In Depth 13 Dec 2023
Revolutionizing glioblastoma treatment: how CAR-T cell therapy could be used as a cure
Find out how CAR-T cell therapy, which has been so groundbreaking in treating blood cancers, could be used to cure glioblastoma.
In Depth
- Latest Posts
In Depth 11 Dec 2023
European patents in biotech: how to prevent invalid patents?
The ongoing patent battle between COVID-19 vaccine giants, Pfizer-BioNTech and Moderna, has seen a new development when the European Patent Office (EPO) invalidated one of Moderna’s patents related to “respiratory virus vaccines.” BioNTech, in collaboration with Pfizer and Sanofi, opposed the patent, leading to its invalidation. The European patent process is complex but essential. As […]
In Depth 7 Dec 2023
The biggest private biotech investments in November 2023
The companies Cambrian Innovation, Terremoto Biosciences, and VectorY Therapeutics bagged the biggest biotech investments in November 2023. Around the world, oncology and central nervous system players attracted the biggest funding rounds. As we edge closer to Christmas, biotech fundraising appears to be drying up a bit; there was a significant decrease in funding rounds in […]
In Depth 30 Nov 2023
Could an Alzheimer’s vaccine make treatment more affordable?
Alzheimer’s research has come a long way since the disease was first identified more than a century ago. Now, as treatments have been developed to reduce the harmful proteins in the brain that are associated with Alzheimer’s, vaccine trials are underway to eliminate these proteins. But how far along are these vaccines in the clinic? […]
In Depth 27 Nov 2023
How are R&D Tax Incentives shaping Australia’s biotech future?
Research and development (R&D) stands as a cornerstone for driving innovation, particularly within the biotech industry. The pivotal role of R&D extends beyond immediate commercial implications and encompasses a broader spectrum of societal and economic benefits. R&D represents significant expense, and if big companies can afford the risk, it may not be the case for […]
In Depth 23 Nov 2023
The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy
Immunotherapy has revolutionized cancer treatment, offering promising avenues beyond traditional methods. Recent breakthroughs showcased at the Society for Immunotherapy of Cancer’s (SITC) annual meeting have spotlighted innovative approaches, notably chimeric antigen receptor macrophage (CAR-M) therapy, offering new strategies in the fight against solid tumors and addressing the limitations of current treatments. Navigating the labyrinth: immunotherapy’s […]
ADVERTISEMENT
ADVERTISEMENT
In Depth 22 Nov 2023
Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment
Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […]
In Depth 16 Nov 2023
uniQure: is the gene therapy pioneer en route to becoming a biotech rebuff?
Once thought to be a frontrunner in gene therapy, uniQure’s fame may no longer be coveted, as the biotech looks to reorganize by slashing its workforce, in an attempt to stay afloat. But how did things go awry for the company that was once in its prime in the DNA game? The Danish company, which […]
In Depth 16 Nov 2023
Meet the ‘biotech mafia’: how specialized biotech VC firms are dominating industry funding once again
Between 2020 and 2022 – largely due to the biotech innovations that came about by the COVID-19 pandemic – there was an influx of generalist investors in the biotech industry, betting big on new technologies like mRNA vaccines. But, now, these investors appear to have backed off, leaving room for specialized biotech venture capital (VC) […]
In Depth 15 Nov 2023
Beyond oil and gas: Biotech’s significant place in the Qatar Investment Authority’s strategy
Since 2020, the Qatar Investment Authority (QIA) has been taking part in important biotech fundings reaching its peak in 2021 and remaining strong in 2023. They recently led a $250 million round in the company BridgeBio specialized in transformative medicine for patients suffering from cancer or genetic diseases. This investment is not an isolated case […]
In Depth 9 Nov 2023
Blood tests for Alzheimer’s: a hit or a miss?
Doctor’s typically diagnose Alzheimer’s with the help of brain imaging and cognitive tests, along with taking a patient’s medical history into account. But lately, blood tests are gaining recognition for its ability to rule out other potential causes of memory loss, and to diagnose Alzheimer’s more quickly. With American healthcare company Labcorp launching its trio […]
In Depth 6 Nov 2023
The biggest private biotech investments in October 2023
The companies Aiolos Bio, MapLight Therapeutics and Agomab Therapeutics bagged the biggest biotech investments in October 2023. Around the world, biomaterials, central nervous system and musculoskeletal disorder players attracted the most investor interest. October 2023 saw a lot of fundraising taking place both in and out of healthcare in the U.S. and Europe. However, the […]
ADVERTISEMENT
